• Publications
  • Influence
Psychiatric and behavioral abnormalities in Wilson's disease.
From the literature and our experience, a relatively consistent picture of psychiatric and behavioral abnormalities in Wilson's disease emerges. The essential elements of this picture are as follows:Expand
  • 153
  • 13
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Copper plays an essential role in promoting angiogenesis. Tumors that become angiogenic acquire the ability to enter a phase of rapid growth and exhibit increased metastatic potential, the majorExpand
  • 311
  • 12
  • PDF
A novel role for XIAP in copper homeostasis through regulation of MURR1
XIAP is a potent suppressor of apoptosis that directly inhibits specific members of the caspase family of cysteine proteases. Here we demonstrate a novel role for XIAP in the control of intracellularExpand
  • 202
  • 12
  • PDF
Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans.
We have utilized an experimental model of human zinc deficiency for study of cytokines production by TH1 and TH2 cells. Additionally, we determined ratios of CD4+ to CD8+ and CD4+ CD45RA+ toExpand
  • 303
  • 11
Serum thymulin in human zinc deficiency.
The activity of thymulin (a thymic hormone) is dependent on the presence of zinc in the molecule. We assayed serum thymulin activity in three models of mildly zinc-deficient (ZD) human subjectsExpand
  • 305
  • 9
  • PDF
Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management
List of Figures. List of Tables. Foreword. Preface. Acknowledgements. 1. Overview of the Disease for the Clinician. 2. The Clinician's Challenge: Recognizing Wilson's Disease. 3. Simple Approaches toExpand
  • 89
  • 9
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
OBJECTIVE To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree ofExpand
  • 226
  • 8
  • PDF
Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.
We describe a patient with Wilson's disease who presented with neurologic disease, was treated with D-penicillamine, and suffered sudden neurologic deterioration coincident with therapy. ReplicateExpand
  • 283
  • 7
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Preclinical and in vitro studies have determined that copper is an important cofactor for angiogenesis. Tetrathiomolybdate (TM) was developed as an effective anticopper therapy for the initialExpand
  • 278
  • 7
  • PDF
Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging.
Thirty-one patients with Wilson's disease were evaluated with detailed neurologic and medical examinations. Mean age (+/- SD) at onset was 21 +/- 5 years and at examination was 28 +/- 6 years. Of theExpand
  • 234
  • 7